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Abstract
QRS interval on the electrocardiogram reflects ventricular depolarization and conduction time, 
and is a risk factor for mortality, sudden death, and heart failure. We performed a genome-wide 
association meta-analysis in 40,407 European-descent individuals from 14 studies, with further 
genotyping in 7170 additional Europeans, and identified 22 loci associated with QRS duration (P 
< 5 × 10−8). These loci map in or near genes in pathways with established roles in ventricular 
conduction such as sodium channels, transcription factors, and calcium-handling proteins, but also 
point to novel biologic processes, such as kinase inhibitors and genes related to tumorigenesis. We 
demonstrate that SCN10A, a gene at our most significant locus, is expressed in the mouse 
ventricular conduction system, and treatment with a selective SCN10A blocker prolongs QRS 
duration. These findings extend our current knowledge of ventricular depolarization and 
conduction.
Search Terms
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The electrocardiographic QRS interval reflects ventricular depolarization and its duration is 
a function of electrophysiological properties within the His-Purkinje system and the 
ventricular myocardium. A diseased ventricular conduction system can lead to life-
threatening bradyarrhythmias, such as heart block, and tachyarrhythmias, such as ventricular 
fibrillation. Longer QRS duration is a predictor of mortality and sudden death in the general 
population and in cohorts with hypertension and coronary artery disease.1–3 In a 
population-based study, prolonged baseline QRS was associated with incident heart failure.4
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Twin and family studies suggest a genetic contribution to QRS duration, with heritability 
estimates of up to 40%.5, 6 Prior candidate gene and smaller genome-wide studies identified 
a limited number of loci associated with QRS duration, supporting the hypothesis of the 
contribution of common genetic variation to QRS duration.7–9 To identify additional loci 
and highlight physiologic processes associated with ventricular conduction, we performed a 
meta-analysis of 14 genome-wide association studies (GWAS) of QRS duration in a total of 
40,407 individuals of European descent, where we adjusted the analyses for age, sex, height, 
and body mass index after appropriate sample exclusions (Methods). After an initial 
discovery phase, we further genotyped selected variants representing nine loci with P-values 
ranging from 1 × 10−6 to 5 × 10−9 in an additional cohort of 7170 European individuals.
Results
Meta-analysis of genome-wide association results
We conducted meta-analyses for approximately 2.5 million single nucleotide 
polymorphisms (SNPs) in 40,407 individuals of European ancestry from 14 GWAS 
(Supplementary Tables 1a and 1b). Overall, 612 variants in 20 loci exceeded our genome-
wide significance P-value threshold of 5 × 10−8 after adjusting for modest genomic inflation 
(λGC = 1.059) (Figure 1 and Supplementary Figure 1). The loci associated with QRS interval 
duration are detailed in Table 1 and Supplementary Figure 2, with the index SNP 
(representing the most significant association) labeled for each independent signal.
Across the genome, the most significant association for QRS interval duration (locus 1) was 
on chromosome 3p22 (Figure 2a), where we identified six potentially independent 
association signals based on the linkage disequilibrium (LD) patterns in HapMap-CEU 
(pairwise r2 among index SNPs < 0.05). In conditional analyses where all six SNPs were 
included in the same regression model, there was compelling evidence that at least four 
SNPs from this region were independently associated with QRS duration (Table 1). Two of 
these associations were in or near SCN10A, a voltage-gated sodium channel gene. Variation 
at this locus was recently associated with QRS duration in two GWAS. The top SNP 
identified in those two studies, rs6795970, was in strong LD with our top signal, rs6801975 
(r2=0.93).8, 9 Two additional signals were identified in SCN5A, a sodium channel gene 
adjacent to SCN10A (Table 1).
The second most significant locus (locus 2) was on chromosome 6p21 near CDKN1A, a 
cyclin dependent kinase inhibitor. The CDKN1A locus was recently associated with QRS 
interval duration in an Icelandic population.9 The index SNP in the prior report, rs1321311, 
was in strong LD with our top signal, rs9470361 (r2=0.88). Another cyclin dependent kinase 
inhibitor (CDKN2C) was located in locus 15, which encompasses several other genes 
including C1orf185, RNF11, and FAF1.
Locus 3 on chromosome 6q22 contains the PLN/SLC35F1/C6orf204/BRD7P3 cluster of 
genes. PLN encodes phospholamban, a key regulator of sarcoplasmic reticulum calcium 
reuptake. Significant associations were found in several other regions harboring calcium-
handling genes, including locus 12 (STRN/HEATR5B), locus 16 (PRKCA), and locus 18 
(CASQ2).
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Locus 4 mapped to an intronic SNP in NFIA, a transcription factor. Several other significant 
loci also mapped in or near transcription factors including locus 5 (HAND1), locus 6 
(TBX20), locus 8 (TBX5), locus 9 (TBX3), and locus 19 (KLF12). Common variation in 
TBX5 was recently associated with QRS duration.9 The index signal in the prior report, 
rs3825214, was in moderate LD with our top signal, rs883079 (r2=0.67).
Additional regions identified include locus 7 (SIPA1L1), locus 10 (VTI1A), locus 11 
(SETBP1), locus 13 (TKT/CACNA1D/PRKCD), locus 14 (CRIM1), locus 17 (nearest gene, 
IGFBP3, is 660kb away), and locus 20 (LRIG1).
Collectively, the identified index SNPs across these 20 loci explained approximately 5.7% 
(±2.3%) of the observed variance in QRS duration, consistent with a polygenic model in 
which each of the discovered variants exerts only a modest effect on QRS interval. None of 
these index SNPs showed a significant interaction with sex or age after Bonferroni 
correction (Supplementary Table 2). We observed moderate levels of heterogeneity of the 
effect (25 < I2 < 75) for several index SNPs (Table 1). However, only HAND1/SAP30L 
showed significant evidence of heterogeneity using Cochran’s Q test corrected for 23 
independent genome-wide variants (Cochran’s P = 0.005).
Extension of findings in an additional 7170 individuals
Based on the discovery meta-analysis, we selected the index SNPs at four loci (loci 15, 17, 
19, and 20) with P-values ranging between 5 × 10−8 and 5 × 10−9 and from all five loci with 
P-values ranging from 1 × 10−6 to 5 × 10−8 (Methods) for genotyping in an additional 7170 
European individuals in order to boost power. In a joint analysis combining all 47,577 
individuals, the significance for the four loci with P-values between 5 × 10−8 and 5 ×10−9 
increased, indicating these represent true positive associations (Table 1). The joint analysis 
also provided further evidence for two other loci (locus 21 near DKK1, and locus 22 tagged 
by an intronic SNP in GOSR2) that reached genome-wide significance, bringing the total 
number of significant loci to 22 with 25 independently associated index SNPs (Table 1). The 
index SNP (rs1733724) in DKK1 was previously associated with QRS duration in an 
Icelandic population.9
Association with conduction defect
Based on this series of QRS associations, we sought to test the hypothesis that QRS 
prolonging alleles, on average, increase risk of ventricular conduction defects. To address 
this question, we calculated a risk score in each individual by adding up the number of QRS 
prolonging alleles identified in this study, weighted by the observed effect sizes (β-
estimates) from the final meta-analysis. In an independent set of 522 individuals from the 
ARIC and RS studies with bundle branch block or nonspecific prolongation of QRS interval 
(QRS>120 ms) compared with those with normal conduction (N = 12,804), each additional 
copy of a QRS prolonging allele was associated with a 8% increase in risk of ventricular 
conduction defect (P = 0.004). This result was largely driven by those with non-specific 
intraventricular conduction defects as opposed to those with left or right bundle branch 
block (Supplementary Tables 3a and 3b). Similar results were observed using an unweighted 
genotype risk score.
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Putative functional variants
Of 612 genome-wide significant SNPs, one in SCN5A (rs1805124, H558R, P = 2.4×10−18), 
two in SCN10A (rs12632942, L1092P, P = 5.1×1011, and rs6795970, A1073V, P = 
5×10−27), one in C6orf204 near PLN (rs3734381, S137G, P=1.1×10−10), and one in CASQ2 
(index SNP rs4074536, T66A, P = 2.4×10−8) were nonsynonymous (Figure 2 and 
Supplementary Figure 2). The PolyPhen-2 program predicts all five of these variants to be 
benign, which is consistent with small-effect associations: each copy of the minor allele was 
associated with cross-sectional differences in QRS duration of less than 1ms.
The 25 index SNPs (from Table 1) were subsequently tested for association with gene cis-
expression levels in 1,240 PAXgene whole blood samples10. Four cis-eQTLs were detected 
after stringent Bonferroni correction (Supplementary Figure 3). The most striking eQTLs 
were observed for probes in exonic regions of TKT (rs4687718, P = 5.87×10−70) and 
CDKN1A (rs9470361, P = 1.41×10−10) and an intronic probe for C6orf204 near PLN 
(rs11153730, P = 1.54×10−10). We additionally assessed cis-regulation for all HapMap 
SNPs for these three loci (± 250kb around the SNPs). The top eSNP for TKT (rs9821134) 
and C6orf204 (rs11970286) were in moderate to high LD (r2 = 0.47 and 0.91, respectively) 
with the top QRS signals at these loci. However, the top eSNP for CDKN1A, rs735013, was 
only weakly correlated with the QRS index SNP rs9470361 (r2 = 0.089). In conditional 
analysis that included both CDKN1A locus SNPs in the regression model, both rs735013 and 
rs9470361 remained independently associated with expression levels (P = 1.7 × 10−9 and 
2.3 × 10−5, respectively). Additionally, rs735013 itself was marginally associated with QRS 
duration (coded allele frequency = 0.39; β = 0.33 ms (±0.07); P = 2.4 × 10–6). Whether 
these associations in whole blood samples will be similar to associations in cardiac 
myocytes and conduction tissue deserves further investigation.
Pleiotropic effects of variants associated with QRS duration and other ECG measurements
To explore the shared genetic underpinnings between atrial and ventricular depolarization 
and conduction (as measured by PR and QRS intervals) as well as ventricular depolarization 
and repolarization (QRS and QT intervals), we examined the effects of published PR and 
QT SNPs with respect to QRS interval. Several QRS loci were previously associated with 
PR or QT intervals, including PLN, TBX5/3, and SCN5A/10A, the last of which is associated 
with all three traits (Supplementary Table 4a). We also tested nine PR SNPs and 16 QT 
SNPs for their effect on QRS duration (Supplementary Table 4b).11–13 Our results suggest 
roles for CAV1/2 (rs3807989, P = 5.8 × 10−6) and NOS1AP (rs12143842, P = 1.3 × 10−4) in 
QRS duration. Indeed CAV1/2 was recently associated with QRS interval.9
QRS duration is positively correlated with both PR interval (r = 0.09) and QT interval (r = 
0.44).9 To test if these relationships are also observed genetically, we compared the 
directionality of the association of SNPs at the published PR and QT loci with those for 
QRS duration. Generally, the effects of SNPs on PR interval were positively correlated with 
their effects on QRS duration (r = 0.53). With the exception of TBX3, the loci influencing 
both PR and QRS (SCN5A, SCN10A, TBX5, and CAV1/2), do so in a concordant fashion (i.e. 
variants that prolong PR also prolong QRS duration) (Figure 3 and Supplementary Tables 4a 
and 4b). By contrast, while QT and QRS are positively correlated at the population level, the 
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effects of SNPs on QT interval were marginally negatively correlated with their effects on 
QRS (r = −0.08). Of the index SNPs at the four loci significantly associated with both QT 
and QRS (SCN5A/SCN10A, PRKCA, NOS1AP, PLN), only the PLN locus SNPs showed 
effects in the same direction (Figure 3 and Supplementary Tables 4a and 4b).
Bioinformatic network analysis of QRS-associated loci
To examine the relationships between genetic loci associated with QRS duration, we 
developed an in silico relational network linking the loci based on published direct gene 
product interactions obtained from curated databases (Supplementary Figure 4).14 Most loci 
meeting genome-wide significance mapped to this network after a minimum number of 
“linker” nodes were incorporated to create a spanning network. This analysis provides a 
graphical overview of the interconnections among QRS-associated genetic loci and 
highlights both known and putative molecular mechanisms regulating ventricular conduction 
(see Discussion). Several of the “linker” nodes incorporated in the network, such as 
calmodulin, connexin 43 (GJA1), NEDD4, KCNMA1, and RYR2 are known modulators of 
cardiac electrical activity. Functional enrichment analysis of the QRS-associated network 
nodes (loci with P <5×10−8) using two independent software tools revealed that programs 
involved in heart development were highly over-represented (P-value range: 5.8×10−6 – 
9.6×10−5).15, 16
Functional effects of the SCN10A locus in a mouse model of cardiac conduction
We undertook functional studies to determine whether our most significant locus was 
associated with ventricular conduction in mice. Transcriptional profiling suggests that 
Scn10a/Nav1.8 mRNA is expressed in ventricular myocardium and at higher levels in the 
specialized conduction system.17 These data were confirmed and extended by qPCR (Figure 
4a), demonstrating a 25.7 ± 1.1 fold enrichment of Scn10a/Nav1.8 in Purkinje cells 
compared to working ventricular myocytes (n=3 for each cell type; p=0.002).
Telemetric electrocardiographic recordings (lead II position) were obtained in conscious 
mice treated with A-803467, a potent Scn10a/Nav1.8 antagonist, which blocks Nav1.8 100 
times more potently than Nav1.5 with the doses used.18 These studies demonstrated a 
significant increase in QRS duration (11.6 ± 2.6 ms to 14.5 ± .54 ms; n = 7; P<0.001), 
whereas vehicle alone was without effect (11.4 ± .29 ms to 11.9 ± .42 ms; n = 7; P=NS). PR 
interval was also increased in drug-treated mice, from 31.4 ± .98 ms to 42.5 ± 3.3 ms; n=7; 
P< 0.01), whereas vehicle alone resulted in no significant change (32.6 ± 1.0 ms to 33.4 ± .
69 ms; n=7; P=NS) (Figure 4b). To further delineate the site of ventricular conduction 
slowing, we performed intra-cardiac recordings from mice treated with A-803467. These 
studies confirmed the significant increase in QRS duration (from 12.26 ± 0.62 ms to 14.56 ± 
0.58 ms; n=7; P =0.015), whereas vehicle alone was without significant effect (12.39 ± 0.52 
ms to 13.65 ± 0.97 ms; n = 5, P = NS). A-803467 treatment resulted in a 35.7% ± 1.2% 
increase in HV interval (from 9.33 ± 0.74 ms to 12.67 ± 1.06 ms; P = .009), whereas vehicle 
alone was without significant effect (10.67 ± .83 ms to 11.17 ± 1.10 ms; P = NS) (Figure 
4c). Taken together, these data indicate that the QRS prolongation may primarily reflect 
conduction slowing in the specialized ventricular conduction system.
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Discussion
Our meta-analysis of 14 genome-wide association studies consisting of 40,407 individuals 
of European descent, with additional genotyping in 7170 Europeans, yielded genome-wide 
significant associations of QRS duration with common variants in 22 loci. Variations in four 
of these loci (locus 1, SCN5A/10A; locus 2, CDKN1A; locus 8, TBX5; and locus 21, DKK1) 
were previously associated with QRS duration in smaller independent studies using both 
candidate gene and genome-wide approaches.7–9 The 22 loci include genes in a number of 
interconnected pathways, including some previously known to be involved in cardiac 
conduction, such as sodium channels, calcium-handling proteins, and transcription factors, 
as well as novel processes not known to be involved in cardiac electrophysiology, such as 
kinase inhibitors, growth factor-related genes, and others.
The electrocardiographic QRS interval reflects ventricular depolarization and conduction 
time. Ventricular myocyte depolarization occurs via cardiac membrane excitatory inward 
currents mediated by voltage-gated sodium channels.19 The primary determinants of 
conduction velocity are the magnitude of excitatory inward currents flowing through these 
sodium channels, the extent of cell-to-cell communication via gap junction/connexin 
coupling, and cell and tissue architecture and morphology.19 Multiple pathways suggested 
in this study determine or modulate these key components of ventricular depolarization and 
conduction. Candidate genes in these pathways are briefly discussed in Box 1.
Box 1
Noteworthy genes within loci associated with QRS duration
Of the 22 loci identified, common variants in four loci (SCN5A/SCN10A, CDKN1A, 
TBX5,and DKK1) were previously associated with QRS duration in genetic association 
studies. Mutations in two (SCN5Aand TBX5) lead to inherited syndromes associated with 
conduction disease. Animal experiments demonstrate a role for several additional loci 
(HAND1, TBX3,andTBX5) in cardiac ventricular conduction, as detailed below. The 
remainder are novel QRS loci, and their role in cardiac conduction remains to be 
elucidated.
1. Cardiac sodium channel genes:
• SCN5A (locus 1): SCN5A encodes the cardiac Nav1.5 sodium channel 
and is well known to influence cardiac conduction, as well as other 
cardiovascular and electrophysiologic phenotypes.20, 21
• SCN10A (locus 1): SCN10A encodes the Nav1.8 sodium channel, present 
in both ventricular myocardium and conduction fibers. Selective SCN10A 
blocker prolongs QRS interval.
2. Calcium handling proteins:
• CASQ2 (locus 18): CASQ2 regulates opening of the ryanodine receptor 
(RYR2).37, 38 Cellular depolarization via Na-channels triggers calcium 
influx through L-type calcium channels, which in turn provokes RYR2-
mediated calcium release from the sarcoplasmic reticulum. CASQ2 
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mutations have been associated with catecholaminergic polymorphic 
ventricular tachycardia.39, 40
• PLN (locus 3): Calcium uptake into the sarcoplasmic reticulum by 
SERCA2a is regulated by phospholamban (PLN).41 The phosphorylation 
state of PLN is dependent on signaling pathways involving phosphatases 
and kinases including PRKCA.41 We previously demonstrated that this 
locus is associated with both cardiac electrical properties (QT interval 
duration, heart rate) and size (left ventricular end diastolic dimension) in 
GWA analyses.11, 12, 42, 43
• PRKCA (locus 16): Protein kinase C alpha activity affects 
dephosphorylation of the sarcoplasmic reticulum Ca2+ ATPase-2 
(SERCA-2) pump inhibitory protein phospholamban (PLN), and alters 
sarcoplasmic reticulum Ca2+ loading and the Ca2+ transient.44
• STRN (locus 12): Striatin is a Ca2+/calmodulin binding protein that 
directly binds to caveolin scaffolding protein. Striatin has recently been 
implicated in a canine model of arrhythmogenic right ventricular 
cardiomyopathy.45, 46
3. Transcription factors:
• TBX3 (locus 9) and TBX5 (locus 8): TBX3 and TBX5 encode 
transcription factors found in the cardiac conduction system. TBX5 
(activator) competes with TBX3 (repressor) for the regulation of working 
myocardial genes such as GJA1.47, 48 Common variations near TBX3 
and TBX5 were associated with PR and QRS durations.9, 13 Mutations in 
TBX3 and TBX5 have been associated with rare inherited syndromes 
manifested by an array of defects including ventricular structural and/or 
conduction defects.
• TBX20 (locus 6): TBX20 demarcates the left and right ventricles49 and 
mutations in TBX20 have been implicated in multiple structural defects in 
mouse and human models.50, 51
• HAND1 (locus 5): HAND1 encodes a transcription factor essential to 
cardiac morphogenesis,52 with a mutation identified in human hearts 
with septal defects.53 Over-expression of Hand1 in the adult mouse heart 
leads to loss of connexin43 (GJA1) expression, QRS prolongation, and 
predisposition to ventricular arrhythmia.54
• NFIA (locus 4) and KLF12 (locus 19): Little is known about the role of 
Nuclear Factor One (NFIA) and Kruppel like protein 12 (KLF12) in 
cardiac tissue development.
4. Cyclin dependent kinase inhibitors:
• CDKN1A (locus 2): CDKN1A is a negative regulator of cell cycle entry 
into G2/M phase, and is upregulated by ERBB2 activation. ERBB2, a 
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member of the EGF receptor family of tyrosine kinases, is essential for 
proper heart development, and its ligand neuregulin-1 promotes 
formation of the murine cardiac conduction system.55 Furthermore, 
ERBB2 can modulate gap junction assembly and alter appropriate 
phosphorylation of connexin 43 in glial cells.56 In addition, CDKN1A is 
upregulated by PRKCA (locus 16).57
• CDKN2C (locus 15): A member of the family of cyclin-dependent kinase 
inhibitors that prevent the activation of the CDK kinases, thus functioning 
as a cell growth regulator that controls cell cycle G1 progression.
5. Other pathways:
• CRIM1 (locus 14): CRIM1 (locus 14), a cell-surface transmembrane 
protein that may bind to various members of the TGF-beta superfamily of 
ligands, is expressed in mouse and human cardiac tissues.58, 59 CRIM1 
interacts with bone morphogenetic proteins, which induce the expression 
of CDKN1A (p21).58, 60
• LRIG1 (locus 20): LRIG1 is upregulated in malignancies. It negatively 
regulates the proto-oncogenic, tyrosine kinase receptor family ERBB2.61
• SETBP1 (locus 11): SETBP1 (locus 11) encodes a ubiquitously 
expressed protein that binds to the SET gene.62 The SETBP1-SET 
interaction has been hypothesized to be a component in tumor 
development.
• TKT (locus 13): Transketolase (TKT) is a ubiquitous enzyme used in 
multiple metabolic pathways, including the pentose phosphate pathway.
63
• DKK1 (locus 21): DKK1, implicated in several tumors, inhibits the Wnt 
signaling pathway.64 Wnt signaling is an important modulator of 
connexin43 dependent intercellular coupling in the heart.65 In cardiac 
tissue it has an embryologic role with regard to axial development.66
• SIPA1L1 (locus 7): SIPA1L1 appears to play a role in non-canonical Wnt 
signaling and contributes to development.67
Our strongest association signal (locus 1) mapped in or near two voltage-gated sodium 
channel genes: SCN5A and SCN10A. SCN5A encodes the cardiac Nav1.5 sodium channel 
and is well known for its role in cardiac conduction, and other cardiovascular and 
electrophysiologic phenotypes.20, 21 SCN10A encodes the Nav1.8 sodium channel. We 
provide novel data demonstrating that the SCN10A transcript and product is preferentially 
expressed in the mouse His-Purkinje system compared with the ventricular myocardium, 
and that Nav1.8 channel blockers result in QRS and HV interval prolongation, indicative of 
a slowing of impulse propagation in the specialized ventricular conduction system and 
delayed activation of the ventricular myocardium. Interestingly, Chambers et al. recently 
reported shortening of the PR interval in Scn10a knockout mice and concluded that Scn10a 
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prolongs cardiac conduction and that rs6795970, encoding a Nav1.8 A1073V variant, is a 
gain-of-function allele.8 Alternatively, the more rapid conduction they observed in the 
knockout mice could reflect compensatory upregulation of TTX-sensitive currents, a 22 
phenomenon observed in Nav1.8-deficient DRG neurons.
We, and others, demonstrated previously that, in addition to their association with QRS 
duration, variants in SCN5A and SCN10A are associated with atrial conduction (PR interval) 
and myocardial repolarization (QT interval), as well as atrial and ventricular fibrillation.8, 9, 
13 These results emphasize the crucial role played by these genes in cardiac conduction and 
the generation of arrhythmias.
Calcium regulation is integral to impulse propagation, modulating cellular electrophysiology 
including sodium channel and gap junction function, as well as tissue architecture.20, 23, 24 
Several of the loci associated with QRS duration contain genes directly related to calcium 
processes. As depicted in Supplementary Figure 4 and detailed in Box 1, these genes encode 
interrelated proteins that influence Ca2+ signaling (PLN in locus 3; PRKCA in locus 16; and 
CASQ2 in locus 18) and downstream effects (STRN in locus 12).
Transcription factors regulating embryonic electrophysiologic development are critical for 
the integrity of impulse conduction.25 We identified six transcription factors (TBX3 in locus 
9; TBX5 in locus 8; TBX20 in locus 6; HAND1 in locus 5; NFIA in locus 4; and KLF12 in 
locus 19) in loci associated with QRS duration. Several of these transcription factors impact 
cardiac morphogenesis and may influence conduction by altering cellular and tissue 
architecture. Intriguingly, they may also have direct electrophysiologic consequences by 
modifying factors involved in impulse conduction. For example, HAND1 and T-box factors 
regulate connexin 40 (GJA5) and/or connexin 43 (GJA1), and TBX5 binds to the ATP2A2 
(SERCA2A) promoter.26
Our study suggests a number of processes and pathways not previously known to be 
involved in cardiac electrophysiology, including cyclin dependent kinase inhibitors and 
genes related to tumorigenesis and cellular transformation. How these novel processes 
influence QRS duration remains to be defined.
In pleiotropic analyses, most variants influencing both PR and QRS, with the exception of 
TBX3, were concordant in effect direction, consistent with the known shared physiologic 
processes underlying the two traits: depolarization and conduction time in the sino-atrial, 
atria and atrioventricular node (PR) and depolarization and conduction time in the ventricles 
(QRS). By contrast, although QRS (ventricular depolarization) and QT (ventricular 
repolarization) are moderately positively correlated, most loci influencing both traits showed 
discordant effect directions (with the exception of the PLN locus). Investigating the 
physiologic foundations for these concordant and discordant PR-QRS and QT-QRS 
relationships could be particularly informative for elucidating the mechanisms by which 
these loci influence cardiac depolarization, conduction and repolarization.
Several limitations of our study should be considered. First, although we have identified 22 
loci significantly associated with QRS duration, the broad nature of linkage disequilibrium 
among common variants generally precludes an unambiguous identification of the culprit 
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variant or of the functional gene. For several genes (SCN5A, SCN10A, C6orf204, CASQ2), 
there are common coding SNPs in high LD with the index SNP, which may lend some 
support for a functional role for these genes. Furthermore, our expression analysis in blood 
revealed very strong cis-eQTL associations for TKT and CDKN1A, lending additional 
support to these genes as functional candidates. It would be desirable to perform similar 
eQTL analyses based on expression data in myocardial cells or conduction tissue. For our 
top signal in SCN10A, a gene which until recently was not known to be expressed in the 
heart, our functional work in mice confirm that SCN10A is involved in ventricular 
depolarization and conduction. Further fine-mapping is needed at all 22 loci to conclusively 
test all genetic variation (rare and common) for a role in QRS modulation.
To minimize the potential for confounding due to population substructure, we limited the 
analyses to individuals of European descent, for whom we could assemble the largest 
number of samples. At the individual study level, the GWAS showed very little evidence for 
gross stratification (genomic inflation factor, λGC, values ranged from 1.00 to 1.05). 
However, one of our QRS loci, mapping to HAND1/SAP30L, showed evidence of 
heterogeneity. In genetic association studies, heterogeneity can be due to sampling error, 
differences in phenotypic measurement, differences in LD structure between populations, 
technical artifacts, or genuine biological heterogeneity, but it would be difficult to conclude 
on the basis of our data here which is the most likely explanation.27
Our study underscores the power of a large genome-wide association study to extend prior 
biological understanding of cardiac ventricular conduction. Better understanding of the 
complex biologic pathways and molecular genetics associated with cardiac conduction and 
QRS duration may offer insight into the molecular basis underlying the pathogenesis of 
conduction abnormalities that can result in increased risk of sudden death, heart failure, and 
cardiac mortality.
Methods
Methods and any associated references are available in the online version of the paper.
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Figure 1. Manhattan plot
Manhattan plot showing the association of SNPs with QRS interval duration in a GWAS of 
40,407 individuals. The dashed horizontal line marks the threshold for genome-wide 
significance (P = 5 × 10−8). Twenty loci (labeled) reached genome-wide significance. Two 
additional loci, GOSR2 and DKK1, reached significance after genotyping of select SNPs in 
an additional sample of 7170 individuals (see Results).
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Figure 2. Association plots for select loci
Each SNP is plotted with respect to its chromosomal location (x-axis) and its P-value (y-axis 
on the left). The tall blue spikes indicate the recombination rate (y-axis on the right) at that 
region of the chromosome. The blue-outlined triangles indicate coding region SNPs. (a) 
Locus 1 (SCN5A/SCN10A) on chromosome 3: The six index signals are named with their rs 
numbers and highlighted in different colors (yellow, green, teal, blue, purple, and red). Other 
SNPs in linkage disequilibrium with the index SNP are denoted in the same color. Color 
saturation indicates the degree of correlation with the index SNP. (b) Locus 8 (TBX5) and 
locus 9 (TBX3) on chromosome 12. (c) Locus 12 (HEATR5B/STRN) and locus 14 (CRIM1) 
on chromosome 2.
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Figure 3. Pleiotropic associations of PR, QRS, and QT loci
Electrocardiographic tracing delineating the PR, QRS, and QT intervals. PR and QRS 
intervals reflect myocardial depolarization and conduction time through the atria and down 
the atrioventricular node (PR) and throughout the ventricle (QRS), and are weakly positively 
correlated (r=0.09). The majority of loci that influence both PR and QRS (SCN5A, SCN10A, 
TBX5, CAV1/2), do so in a concordant fashion (i.e. variants that prolong PR also prolong 
QRS duration). The notable exception is a region on chromosome 12, where variants in the 
TBX5 locus have a concordant effect whereas those in nearby TBX3 have a discordant effect. 
By contrast, although QRS (ventricular depolarization) and QT (ventricular repolarization) 
are moderately positively correlated, the majority of loci (SCN5A, SCN10A, PRKCA, 
NOS1AP) that influence both phenotypes do so in a discordant fashion (i.e. variants that 
prolong QRS shorten the QT interval). The exception is the locus at PLN, where variants 
have a concordant effect.
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Figure 4. Expression and function of Scn10a in the murine heart
Panel A. Neonatal ventricular myocytes from Cntn2-EGFP BAC transgenic mice were 
FACS sorted and EGFP+ and EGFP- pools were analyzed by RT-PCR. Transcripts encoding 
EGFP, Cntn2 and Scn10a were highly enriched in the EGFP+ fraction. Quantitative RT-
PCR demonstrated 25.7 fold enrichment of Scn10a/Nav1.8. Panel B. Representative 
telemetric electrocardiographic recordings (lead II configuration) obtained 30 minutes after 
administration of vehicle alone (black tracing) or the Scn10a/Nav1.8 antagonist A-803467 
(green tracing). The two tracings are aligned at the onset of the QRS wave and both PR 
interval and QRS interval prolongation were observed in drug-treated mice. Panel C. 
Representative intracardiac recordings showing HV intervals obtained prior to (Pre) and 
after (Post) administration of vehicle or A-803467. Significant HV prolongation was 
observed in drug-treated mice.
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